1. Home
  2. ANL vs IVVD Comparison

ANL vs IVVD Comparison

Compare ANL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$7.98

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.83

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
IVVD
Founded
2004
2020
Country
Cayman Islands
United States
Employees
123
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.4M
437.1M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ANL
IVVD
Price
$7.98
$1.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$16.00
$8.75
AVG Volume (30 Days)
215.2K
1.6M
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$143.48
Revenue Next Year
N/A
$25.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$0.88
$0.46
52 Week High
$12.09
$3.07

Technical Indicators

Market Signals
Indicator
ANL
IVVD
Relative Strength Index (RSI) 47.12 51.65
Support Level $7.21 $1.41
Resistance Level $9.98 $2.01
Average True Range (ATR) 1.05 0.11
MACD -0.31 0.04
Stochastic Oscillator 25.68 57.32

Price Performance

Historical Comparison
ANL
IVVD

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: